Chemours(US:CC)2026-02-19 21:40Financial Performance - Q4 2025 Net Sales were $1.3 billion, down 2% year-over-year, primarily due to a 4% decrease in volume, partially offset by a 1% price increase and a 1% currency tailwind [7]. - Q4 2025 Net Loss attributable to Chemours was $47 million, or $0.31 per diluted share, compared to a Net Loss of $11 million, or $0.08 per diluted share in Q4 2024 [8]. - Adjusted EBITDA for Q4 2025 was $128 million, down 24% from $168 million in the prior-year quarter, driven by higher costs impacting net loss [8]. - Full year 2025 Net Sales were $5.8 billion, flat compared to the prior year, with TSS reporting record annual sales driven by higher volume and price [9]. - Full year 2025 Net Loss attributable to Chemours was $386 million, or $2.57 per diluted share, compared to Net Income of $69 million, or $0.46 per diluted share in the prior year [10]. - Adjusted EBITDA for the full year 2025 was $742 million, down from $768 million in the prior year, primarily due to lower pricing and cost absorption issues [10]. Segment Performance - TSS segment Q4 2025 Net Sales were $444 million, a 14% increase year-over-year, driven by a 10% price increase and a 3% volume increase [12]. - TiO2 segment Q4 2025 Net Sales were $561 million, an 11% decrease year-over-year, primarily due to a 6% decrease in price globally [17]. - APM segment Q4 2025 Net Sales were $312 million, a 4% decrease year-over-year, primarily driven by an 8% decrease in volume [21]. - APM segment Q4 2025 Adjusted EBITDA decreased 74% to $12 million, primarily due to a non-cash inventory charge and a less favorable product mix [23]. - APM segment full year 2025 Net Sales were $1.3 billion, a 5% decrease compared to full year 2024, primarily due to weaker global demand [25]. - Adjusted EBITDA for APM decreased 32% from the prior year to $108 million, driven by lower cost absorption and operational disruptions [25]. - Other Non-Reportable Segment had Net Sales of $50 million and Adjusted EBITDA of $8 million for the full year 2025 [26]. Cash Flow and Debt - Free Cash Flows for Q4 2025 were $92 million, reflecting a Free Cash Flow Conversion of 72%, compared to $29 million or 17% in Q4 2024 [30]. - As of December 31, 2025, consolidated gross debt was $4.2 billion, with a net leverage ratio of approximately 4.7x on a trailing twelve-month Adjusted EBITDA basis [28]. - Cash provided by operating activities was $264 million for the year ended December 31, 2025, a significant improvement from cash used of $633 million in 2024 [51]. - Cash used for investing activities was $206 million for the year ended December 31, 2025, compared to $353 million in 2024 [51]. - The company issued $748 million in new debt during the year ended December 31, 2025, compared to $606 million in 2024 [51]. Future Outlook - The Company anticipates consolidated Net Sales to increase by 3 to 5% in Q1 2026, with Adjusted EBITDA expected to range between $120 million and $150 million [31]. - The Company expects 2026 Net Sales growth in the range of 3 to 5% and Adjusted EBITDA of $800 million to $900 million [37]. - Capital expenditures for 2026 are anticipated to range from $275 million to $325 million, with Free Cash Flow Conversion above 25% [37]. - Estimated Free Cash Flows for the year ending December 31, 2026, are projected to be between $200 million and $270 million [67]. - Estimated Adjusted EBITDA for the year ending December 31, 2026, is expected to range from $800 million to $900 million [68]. - Net income attributable to Chemours for the year ending December 31, 2026, is estimated to be between $165 million and $225 million [68]. - Adjusted Net Income for the year ending December 31, 2026, is projected to be between $130 million and $180 million [68]. Legal and Environmental Charges - The company incurred restructuring and asset-related charges of $58 million for the year ended December 31, 2025, primarily related to the exit of the SPS Capstone™ business [59]. - Litigation-related charges for the year ended December 31, 2025, amounted to $320 million, significantly impacting the financial results due to various legal settlements [59]. - Environmental charges for the year ended December 31, 2025, included $93 million related to remediation expenses, reflecting ongoing liabilities [59]. Shareholder Information - Basic loss per share for the year ended December 31, 2025, was $(2.57), while adjusted diluted earnings per share were $0.95, down from $1.20 in 2024 [62]. - The weighted-average number of common shares outstanding for the year ended December 31, 2025, was approximately 150.8 million [62].